


# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-75)	CAFICRESTAT
PRONUNCIATION	ka fik' res tat
THERAPEUTIC CLAIM	Treatment of Diabetic Cardiomyopathy (DbCM)

## CHEMICAL NAMES

1. Pyrazino[2,3-d]pyridazine-5-acetic acid, 7,8-dihydro-8-oxo-7-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]- (Source: CAS)
2. (2-(8-oxo-7-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetic acid (Source: ChemDraw)
3. (8-oxo-7-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetic acid (Source: WHO pINN list 124)

## STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>17</sub> H <sub>10</sub> F <sub>3</sub> N <sub>5</sub> O <sub>3</sub> S
MOLECULAR WEIGHT	421.35
TRADEMARKS	None yet
SPONSOR	Applied Therapeutics
DESIGNATION CODES	AT-001
CAS REGISTRY NUMBER	1355612-71-3
UNII	E8I3O45DDU
WHO NUMBER	11609

## SCS